OCUL

$6.82+1.34%visit website

OCULAR THERAPEUTIX, INC

Market Cap

$1.5B

Live price × SEC shares (Jul 31, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

1.19

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

28.8

TTM to Jun 2026 · revenue

P/B

2.9

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	14,544	13,250	10,785	13,475	52,054
Cost of revenue	1,774	1,594	1,329	2,011	6,708
Research & development	52,358	50,800	66,213	54,138	223,509
Operating income	(68,698)	(69,760)	(93,340)	(82,109)	(313,907)
Interest expense	3,002	2,832	2,777	2,792	11,403
Net income	(69,418)	(64,654)	(88,612)	(78,763)	(301,447)
EPS (basic) ($)	(0.38)		(0.40)	(0.35)	(1.40)
EPS (diluted) ($)	(0.38)		(0.40)	(0.35)	(1.40)
Weighted avg. shares (basic)	183,920		224,099	224,952
Weighted avg. shares (diluted)	183,920		224,099	224,952

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 3, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 50 more quarters, back to Mar 2013, with Tormere Pro.

Corporate Events (8-K)

10 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Oct 16, 2026 accepted 8:15 PM ET	5.02Officer / director change	Document SEC ↗
Aug 3, 2026 accepted 11:07 AM ET	2.02Earnings release	Document SEC ↗
Jun 12, 2026 accepted 8:23 PM ET	5.02Officer / director change5.07Shareholder vote	Document SEC ↗
May 5, 2026 accepted 11:06 AM ET	2.02Earnings release	Document SEC ↗
Feb 27, 2026 accepted 9:02 PM ET	7.01Reg FD disclosure	Document SEC ↗
Feb 5, 2026 accepted 12:13 PM ET	2.02Earnings release	Document SEC ↗
Jan 23, 2026 accepted 12:00 PM ET	5.02Officer / director change	Document SEC ↗
Dec 18, 2025 accepted 9:30 PM ET	8.01Other events	Document SEC ↗
Dec 5, 2025 accepted 10:17 PM ET	8.01Other events	Document SEC ↗
Nov 4, 2025 accepted 12:19 PM ET	2.02Earnings release	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

46%

W/W -1.8pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Velocity Score

6.42x

Avg Daily Selling (90d)

709 sh/day

Baseline Daily Selling

306 sh/day

Unique Sellers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-10-08	2026-10-13	Anderman Todd	Chief Legal Officer	Sale	12.0K	$7.29	$87K	140.5K	View
2026-10-02	2026-10-06	Heier Jeffrey S.	Chief Scientific Officer	Sale	10.9K	$7.05	$77K	307.5K	View
2026-10-02	2026-10-06	Kaiser Peter	Chief Development Officer	Sale	9,990	$7.05	$70K	254.4K	View
2026-08-31	2026-09-02	Notman Donald	Chief Operating Officer	Sale	1,099	$10.24	$11K	366.5K	View
2026-08-24	2026-08-26	Dugel Pravin	Director & See Remarks	Sale	21.6K	$10.77	$233K	2.53M	View

1–5 of 19

1 / 4

Recent News

Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates

Yahoo · 2026-11-03

Ocular Therapeutix, Inc. (OCUL) Stock Price, News, Quote & History

Yahoo! Finance Canada · 2026-11-02

Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026

Yahoo · 2026-11-02

A Nov. 9 webcast is planned to cover Ocular Therapeutix's third-quarter results.

Stock Titan · 2026-11-02

Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

Yahoo · 2026-10-29

Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity

SeekingAlpha · 2026-10-25

Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript

SeekingAlpha · 2026-10-23

Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win

Yahoo · 2026-10-20

Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

Benzinga · 2026-10-19

Ocular Therapeutix (OCUL) Stock May Be Fully Priced Given Its Sales Base

Simply Wall St · 2026-10-18

Novavax, Ocular Therapeutix, and QuidelOrtho Shares Plummet, What You Need To Know

Yahoo · 2026-10-16

Ocular Therapeutix, Inc. (OCUL) Presents at American Academy of Ophthalmology Retina Subspeciality Day - Slideshow

SeekingAlpha · 2026-10-15

1 Russell 2000 Stock with Solid Fundamentals and 2 We Avoid

Yahoo · 2026-10-15

3 Healthcare Stocks We Find Risky

Yahoo · 2026-10-13

3 Unprofitable Stocks Walking a Fine Line

Yahoo · 2026-10-12

Informational purposes only, not investment advice.

OCUL

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

OCULAR THERAPEUTIX, INC (OCUL)

Reporting Insiders

Factor Profile

Corporate Events (8-K)

Date	Insider	Type	Shares	Value
2026-10-08	Anderman Todd	S	11,984	$87,363.36
2026-10-02	Heier Jeffrey S.	S	10,869	$76,626.45
2026-10-02	Kaiser Peter	S	9,990	$70,429.5
2026-08-31	Notman Donald	S	1,099	$11,253.76
2026-08-24	Dugel Pravin	S	21,649	$233,159.73